HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrew R Blight Selected Research

4-Aminopyridine (4 Aminopyridine)

2/2017Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot Study.
12/2015Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
9/2015Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
5/2015Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.
11/2014Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
1/2014A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.
1/2014Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label study.
7/2013Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion.
4/2013Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
5/2012The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrew R Blight Research Topics

Disease

15Multiple Sclerosis
12/2015 - 02/2009
8Spinal Cord Injuries (Spinal Cord Injury)
01/2019 - 07/2003
3Seizures (Absence Seizure)
02/2017 - 01/2012
1Cerebral Palsy (Spastic Diplegia)
02/2017
1Demyelinating Diseases (Demyelinating Disease)
11/2014
1Stroke (Strokes)
07/2013
1Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
07/2013
1Nervous System Diseases (Neurological Disorders)
03/2011
1Torsades de Pointes (Torsade de Pointes)
09/2009
1Dizziness (Lightheadedness)
02/2009
1Neurologic Manifestations (Neurological Manifestations)
06/2006
1Contusions
02/2005

Drug/Important Bio-Agent (IBA)

164-Aminopyridine (4 Aminopyridine)FDA Link
02/2017 - 07/2003
9TabletsIBA
12/2015 - 10/2009
5Potassium Channel Blockers (Blockers, Potassium Channel)IBA
07/2013 - 01/2004
3Pharmaceutical PreparationsIBA
02/2017 - 02/2009
3Potassium Channels (Potassium Channel)IBA
11/2014 - 07/2003
2Chondroitinases and Chondroitin LyasesIBA
01/2019 - 02/2005
1EnzymesIBA
01/2019
1Chondroitin Sulfate ProteoglycansIBA
01/2019
1Delayed-Action PreparationsIBA
11/2014
1Ether (Diethyl Ether)IBA
09/2009
14-chloro-3-hydroxyanthranilic acidIBA
06/2006
1NeurotoxinsIBA
06/2006
1Quinolinic AcidIBA
06/2006
1PenicillinaseIBA
02/2005

Therapy/Procedure

1Investigational Therapies (Experimental Therapy)
01/2018
1Physical Therapy Modalities (Physical Therapy Technique)
07/2013
1Therapeutics
08/2011
1Surgical Instruments (Clip)
02/2005
1Catheters
02/2005